

PharmAust to be granted European Patent relating to the use of MPL Combinations in Cancer

- **The Patent covers pharmaceutical combinations between MPL and other drugs for cancer treatment**
- **European Patent Office Issues Notice to Grant for patent MPL-3, held by Pitney Pharmaceuticals Pty Limited, a wholly owned subsidiary of PharmAust**
- **The patent will be published on 8 March 2023 under number EP3062790**

28 February 2023 – Perth, Australia: PharmAust Limited (ASX: PAA & PAAO), a clinical-stage biotechnology company evaluating the use of Monepantel (MPL) in Cancer and Motor Neurone Disease (MND), is pleased to announce that the European Patent Office has issued a Notice to Grant for this key patent relating to the use of MPL Combinations in Cancer. The Patent covers pharmaceutical combinations between MPL and other drugs that treat cancer. Combination-drug therapy is widespread in cancer treatment, where the therapeutic regimen aims to minimise the possibility of drug resistance.

This key patent coverage relates to pharmaceutical combinations comprising mTOR pathway-interfering drugs and anticancer compounds for particular use in cancer treatment.

mTOR pathway-interfering drugs refer to different drugs which stop the signalling pathway in our cells that help their growth and survival. PharmAust is trialling MPL and other drug combinations to interfere with this pathway as a potential way to treat cancer and neurodegenerative diseases.

The key patent will be published on 8 March 2023 under number EP3062790. PharmAust will receive the Certificate of Grant and the published patent specification.

This patent extends PharmAust's existing patent coverage, including granted patents in Australia, the US, China, Japan, Korea, Canada and New Zealand.

The Board authorises this announcement.

Enquiries:

Anusha Aubert
Investor Relations
investorenquiries@pharmaust.com

P +61 (8) 9202 6814
F +61 (8) 9467 6111
W www.pharmaust.com



About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (PAA) and the Frankfurt Stock Exchange (ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epichem, a highly successful contract medicinal chemistry company that generated \$3.4 million in sales of goods & services in FY 2022.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL showed objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treating human and veterinary cancers and neurodegenerative diseases as it advances a reformulated version of this drug through Phase 1 and 2 clinical trials.